Literature DB >> 14583625

An engineered hyaluronan synthase: characterization for recombinant human hyaluronan synthase 2 Escherichia coli.

Hiroko Hoshi1, Hiroaki Nakagawa, Susumu Nishiguchi, Kazumichi Iwata, Kenichi Niikura, Kenji Monde, Shin-Ichiro Nishimura.   

Abstract

The Class I hyaluronan synthase (HAS) is a unique glycosyltransferase synthesizing hyaluronan (HA), a polysaccharide composed of GlcUA and GlcNAc, by using one catalytic domain that elongates two different monosaccharides. As for the synthetic mechanism, there are two alternative manners for the sugar elongation process. Some bacterial HASs add new sugars to the non-reducing end of the acceptor to grow polymers. On the other hand, some vertebrate enzymes seem to transfer sugars to the reducing end. Expression of vertebrate HASs as active and soluble proteins will accelerate further precise insight into mechanisms of sugar elongation reactions by natural HASs. Since large scale production of HA polymers and oligomers would become powerful tools both for basic studies and new biotechnology to create functional carbohydrates in medicinal purposes, advent of an efficient method for the expression of HASs in Escherichia coli is strongly expected. Here we communicate the first success of the production of recombinant human HAS2 proteins composed of only the catalytic region in E. coli as the active form. It was demonstrated that an engineered HAS2 expressed in E. coli exhibited significant activity to synthesize a mixture of HAS oligomers from 8-mer (HA8) to 16-mer (HA16). Engineered HAS2 prepared herein elongated sugars from exogenous tetrasaccharide to form polymers with a direction to the non-reducing end. According to the present results, large scale production of engineered recombinant HASs is to be performed using E. coli that will provide practical and economic advantages in manufacturing enzymes for use in the synthesis of various oligomeric HA molecules and their industrial applications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583625     DOI: 10.1074/jbc.M305723200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

Review 1.  CS lyases: structure, activity, and applications in analysis and the treatment of diseases.

Authors:  Robert J Linhardt; Fikri Y Avci; Toshihiko Toida; Yeong Shik Kim; Miroslaw Cygler
Journal:  Adv Pharmacol       Date:  2006

2.  Hyaluronan biosynthesis by class I streptococcal hyaluronan synthases occurs at the reducing end.

Authors:  Valarie L Tlapak-Simmons; Christina A Baron; Russell Gotschall; Dewan Haque; William M Canfield; Paul H Weigel
Journal:  J Biol Chem       Date:  2005-01-24       Impact factor: 5.157

3.  Glycoblotting-based high throughput protocol for the structural characterization of hyaluronan degradation products during enzymatic fragmentation.

Authors:  Takayuki Furukawa; Misaki Arai; Fayna Garcia-Martin; Maho Amano; Hiroshi Hinou; Shin-Ichiro Nishimura
Journal:  Glycoconj J       Date:  2012-05-26       Impact factor: 2.916

4.  Biosynthesis of hyaluronan: direction of chain elongation.

Authors:  Peter Prehm
Journal:  Biochem J       Date:  2006-09-15       Impact factor: 3.857

Review 5.  Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2003-2004.

Authors:  David J Harvey
Journal:  Mass Spectrom Rev       Date:  2009 Mar-Apr       Impact factor: 10.946

6.  Characterization of the lipid linkage region and chain length of the cellubiuronic acid capsule of Streptococcus pneumoniae.

Authors:  W Thomas Forsee; Robert T Cartee; Janet Yother
Journal:  J Biol Chem       Date:  2009-02-19       Impact factor: 5.157

Review 7.  Genetic basis for hyper production of hyaluronic acid in natural and engineered microorganisms.

Authors:  Juliana Davies de Oliveira; Lucas Silva Carvalho; Antônio Milton Vieira Gomes; Lúcio Rezende Queiroz; Beatriz Simas Magalhães; Nádia Skorupa Parachin
Journal:  Microb Cell Fact       Date:  2016-07-01       Impact factor: 5.328

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.